US Stock Market Move | Novo Nordisk A/S Sponsored ADR Class B (NVO.US) increased its bid for Metsera (MTSR.US) by over 15%.

On Tuesday, the stock price of Metsera (MTSR.US) rose, and as of the time of publication, the stock had increased by over 15%, reaching $70.42. On the news front, the bidding offer from Pfizer Inc. (PFE.US) and Novo Nordisk A/S Sponsored ADR Class B (NVO.US) was further increased. Metsera issued a statement on the same day, stating that the latest acquisition proposal submitted by Novo Nordisk A/S Sponsored ADR Class B was still considered the "more advantageous" offer by the company's board of directors, and officially notified Pfizer Inc. to submit better conditions within two working days, otherwise they would lose their bidding qualification. According to the latest offer, Novo Nordisk A/S Sponsored ADR Class B has increased the acquisition price to a total value of $86.20 per share, with a transaction size of approximately $10 billion. This includes a cash offer of $62.20 per share (previously $56.50) and a potential value of up to $24 per share in contingent value rights (previously $21.25), with additional cash earnings for shareholders if certain drug pipeline milestones are reached. In comparison, Pfizer Inc.'s recent updated offer is only around $70 per share, with a total value of about $8.1 billion, significantly lower than the proposal from Novo Nordisk A/S Sponsored ADR Class B, and therefore considered a "inferior offer." This bidding war focuses on Metsera's core assets, including late-stage R&D candidate drugs for weight loss and metabolic diseases, seen as potential "next-generation hot products" after Wegovy and Zepbound. With the rapid expansion of the global obesity treatment market, innovative pharmaceutical companies are speeding up their strategic positioning. According to Morgan Stanley's estimates, the global weight loss drug market is expected to exceed $100 billion by 2030. Industry insiders point out that the competition between Pfizer Inc. and Novo Nordisk A/S Sponsored ADR Class B not only involves the merger premium but also reflects the pressure faced by large pharmaceutical companies due to patent expirations and the need to fill product pipelines. If Pfizer Inc. fails to submit a higher bid within the specified time frame, there is a possibility of an early exit from the competition. The market will continue to pay attention to whether Pfizer Inc. will increase its bid in the next 48 hours, and the final direction of the transaction by the Metsera board of directors.